Tim Brons | IR |
Roger Lias | President of Avid Bioservices |
Paul Lytle | CFO |
Tarun Aswani | NOBLE Capital Markets |
Good day, ladies and gentlemen, and welcome to the Peregrine Pharmaceuticals Second Quarter Fiscal 2018 Financial Results Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question-and-answer session and our instructions will follow at that time.
As a reminder, this conference may be recorded. I would now like to hand the conference over to Tim Brons of Peregrine’s Investor Relations Group.